FDA Approves BUPRENORPHINE HYDROCHLORIDE — Advagen Pharma Ltd

Advagen Pharma Ltd has received FDA approval for its Abbreviated New Drug Application (ANDA090279) to market buprenorphine hydrochloride tablets for sublingual use, expanding the Therapeutic Alternatives (TA) anti-addiction portfolio. This approval grants Advagen the rights to produce and distribute the product, allowing the company to capitalize on the ongoing U.S. economic opportunity within the opioid addiction market.